Piermont Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Piermont Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$1.37M	Buy	89,910 +2,000	+2%	+$38.1K	0.65%	81
2018 Q3	$1.76M	Sell	87,910 -16,460	-16%	-$375K	0.71%	81
2018 Q2	$2.04M	Buy	104,370 +4,100	+4%	+$90.7K	0.62%	82
2018 Q1	$2.02M	Buy	100,270 +87,160	+665%	+$1.47M	0.67%	56
2017 Q4	$174K	Buy	+13,110	New	+$198K	0.06%	234
2017 Q3	–	Sell	-12,670	Closed	-$233K	–	280
2017 Q2	$233K	Sell	12,670 -2,280	-15%	-$45.2K	0.07%	245
2017 Q1	$337K	Hold	14,950	–	–	0.08%	241
2016 Q4	$520K	Buy	+14,950	New	+$447K	0.12%	222
2015 Q4	–	Sell	-11,010	Closed	-$437K	–	267
2015 Q3	$437K	Buy	+11,010	New	+$683K	0.14%	160

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Piermont Capital Management's AMAG Position: Q4 2018 in Review

Piermont Capital Management increased its AMAG Pharmaceuticals (AMAG) stake by 2.3% in Q4 2018, buying an estimated $38.1K and bringing the position to 89,910 shares worth $1.37M. The position accounts for 0.65% of the portfolio, ranked #81.

Piermont Capital Management first reported a position in AMAG in Q3 2015 and has held it in 9 quarters since. The position peaked at $2.04M in Q2 2018. 190 funds tracked by Wall St. Rank hold AMAG as of Q4 2018.

Piermont Capital Management held 89,910 shares of AMAG Pharmaceuticals worth $1.37M as of Q4 2018.
Piermont Capital Management bought 2,000 AMAG Pharmaceuticals shares in Q4 2018, an estimated $38.1K.
AMAG Pharmaceuticals made up 0.65% of Piermont Capital Management's portfolio in Q4 2018, its #81 holding.
Piermont Capital Management first reported a position in AMAG Pharmaceuticals in Q3 2015 and has held it in 9 quarters since.
Piermont Capital Management's AMAG Pharmaceuticals position peaked at $2.04M in Q2 2018.
190 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2018.

Based on Piermont Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.